Royalties & Contingent Income

How to Underwrite a Pharma Royalty Stream

Underwrite a pharma royalty by forecasting net sales of the drug through loss of exclusivity, applying the contract's royalty tiers, step-downs and territories, and discounting the result. The drivers are the sales curve, the patent and regulatory exclusivity cliff, competitive entry, and the commercial strength of the company marketing the product.

What makes pharma royalty stream underwriting different

A pharma royalty is a right to a percentage of a drug's net sales, usually created when a university, biotech or inventor licensed the molecule to a company that commercialized it. What makes it distinct is the hard cliff: royalties often fall sharply when patents and regulatory exclusivity end and generic or biosimilar competition arrives. Value comes from approved products with growing sales and long remaining exclusivity. Risk comes from slower uptake, new competitors, safety issues, pricing pressure, patent challenges and royalty step-downs written into the license. Pre-approval royalties add clinical and regulatory risk on top of commercial risk.

Royalty funds buying approved product royalties underwrite sales forecasts, exclusivity and the marketer's commercial execution, and often pay a price implying a target unlevered return. Lenders to royalty holders advance against conservative sales projections and want royalties paid into controlled accounts. Biotechs selling synthetic royalties, newly created royalties on their own products, weigh cost of capital against equity dilution and give up a share of future upside. Investors in development-stage royalties must also judge trial data, approval probability and launch timing, which makes outcomes far more binary.

Key metrics

Forecast net sales

Royalties are a percentage of net sales, so the sales curve is the core driver.

Royalty rate and tiers

Tiered rates, caps and step-downs change effective royalty income at different sales levels.

Loss of exclusivity date

Patent expiry and regulatory exclusivity determine when generic or biosimilar competition begins.

Marketer financial strength

The marketing company's commercial resources and credit affect sales performance and payment reliability.

Probability of technical and regulatory success

For unapproved products, approval odds drive expected value.

Gross-to-net adjustments

Rebates and discounts reduce net sales and can change significantly over time.

How to underwrite it, step by step

Review the license agreement, royalty definitions, tiers, step-downs and territories.
Analyze historical sales and build a forecast through loss of exclusivity.
Assess patents, regulatory exclusivity and pending challenges with counsel.
Evaluate competitive products and pipeline threats.
Review the marketer's commercial plan and financial strength.
Model royalty cash flows and discount at a risk-adjusted rate.
Structure the purchase or financing with appropriate protections.

Due diligence checklist

License agreement and amendments
Royalty reports
Product sales data
Patent portfolio and exclusivity analysis
Regulatory approvals and labels
Clinical data for pipeline indications
Market research and competitor analysis
Marketer financial statements
Audit rights and audit history
Assignment and consent documents

Key risks and mitigants

Sales below forecast

Use conservative uptake assumptions and stress sales curves.

Earlier generic or biosimilar entry

Analyze patent challenges and model early loss of exclusivity scenarios.

Royalty step-downs or offsets

Review license terms carefully and model all reductions.

Safety or regulatory issues

Diligence safety data and label risk and diversify across products.

Marketer deprioritizes the product

Assess the product's importance to the marketer and include information rights.

Typical financing and deal structure

Pharma royalties are monetized through outright sales of royalty interests, partial interest sales, royalty-backed loans and synthetic royalty financings. Buyers may pay upfront plus milestones tied to approvals or sales thresholds. Lenders size loans against projected royalties with coverage covenants and controlled accounts, and some structures cap total payments at a multiple of the purchase price. Synthetic royalties are created by a company selling a percentage of its own product sales. Purchase agreements address audit rights, information rights and the assignment consent of the marketer where required. Some deals include put or call options if sales thresholds are missed.

Red flags

Royalty forecasts relying on aggressive uptake
Pending patent litigation on key patents
Significant royalty step-downs soon after purchase
Marketer with weak commercial capabilities
Unclear royalty definitions or net sales deductions

Frequently asked questions

How are pharma royalties valued?

Pharma royalties are valued by forecasting net sales of the product, applying royalty tiers and contract adjustments, and discounting the resulting cash flows through loss of exclusivity. For unapproved products, forecasts are probability-weighted for clinical and regulatory success. Patent strength, competition and marketer performance are key drivers of value.

What is a synthetic royalty?

A synthetic royalty is a newly created royalty that a company sells on its own product's future sales. The company receives upfront capital and pays a percentage of sales to the investor. It can be less dilutive than equity, but it reduces the company's future revenue and may carry caps or minimum return terms.

Why does loss of exclusivity matter?

Loss of exclusivity marks when generic or biosimilar competitors can enter the market. Sales of the original product often decline sharply afterward, reducing royalties. Underwriters model exclusivity dates and potential early entry from patent challenges because they define the duration of royalty income. Small-molecule drugs and biologics face different erosion patterns after exclusivity ends.

Who buys pharmaceutical royalties?

Buyers include specialized royalty funds, credit funds, pharmaceutical companies and institutional investors. Sellers include universities, research institutes, inventors and biotech companies seeking non-dilutive capital. Buyers evaluate product sales, exclusivity, competitive landscape and contract terms before setting price. Sellers often prefer partial sales to keep some upside.

Underwrite a pharma royalty stream deal in minutes

Drop a deck or data room. Underridge returns a verdict, investment memo, term sheet and a live model, with every headline figure traced to a page, a formula or a labeled assumption. Ten underwrites free.

Try Underridge free

Educational content, not investment, credit, legal or tax advice. Benchmarks are common practitioner rules of thumb and vary by lender, market and cycle.